The United Kingdom and the United States have hammered out a major bilateral deal that will preserve no import taxes on UK pharmaceutical shipments being sold in the US market.
The Terms of the Accord
In exchange for the tariff guarantee, the UK has pledged to increase spending on drugs through the public health system. This pledge ensures that import taxes on these key products will remain at zero for a duration of three years.
This deal comes after previous statements to significantly raise import taxes on branded pharmaceutical products, with increases floated reaching double the cost.
"This arrangement with the United Kingdom reinforces the global environment for innovative medicines and introduces much-needed balance to American-British pharmaceutical trade," a statement declared.
Economic Importance
Pharmaceuticals represent one of the the United Kingdom's largest exports to the America, which is by far the largest buyer for leading UK drugmakers.
Statistics indicate that in the one-year period leading up to last September, the UK exported pharmaceutical products worth over eleven billion pounds to the US. This value accounted for nearly one-fifth of British export trade in that timeframe.
"This agreement secures employment, stimulates investment and paves the way for the UK to emerge as a global hub for life sciences," a minister stated.
Specific NHS Changes
The deal includes several specific pledges from the United Kingdom:
- Revised Affordability Limit: The UK will lift the affordability limit at which it considers new treatments to be too expensive by a quarter.
- Boosted Medicine Funding: There is a aim to increase total public funding on medicines from 0.3% of the national economy to 0.6% over the coming ten years.
- Rebate Cap: The sum drug companies must refund to the NHS to prevent overspending will be restricted at fifteen percent. In the past, refunds exceeded 20%.
Broader Context
The deal comes amid a long-running dispute between the drug companies and the ministers over medicine costs and approval rates.
This friction were intensified by claims that American patients were paying several times more for the identical medicines than patients in the Britain and the EU.
Recently, several major pharmaceutical investments in the UK have been paused or abandoned, while major investments have been pledged toward projects in the United States.
The Science Minister stated that the NHS had to spend more on drugs, noting that its expenditure on drugs had decreased as a proportion of its resources over the last ten years.
